article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Impaired T cell IRE1?/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction

Journal of Clinical Investigation - Cardiology

Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.

article thumbnail

Right ventricular function and anemia in heart failure with preserved ejection fraction

Frontiers in Cardiovascular Medicine

Multivariate linear regression analysis shows that the degree of anemia, atrial fibrillation, and TR were independently associated with the TAPSE/PASP ratio.ConclusionAnemia in HFpEF is associated with RV dysfunction, and this relationship is not affected by classical risk factors, such as smoking, hypertension, and diabetes.

article thumbnail

Pulse pressure and aortic valve peak velocity as new predictors of heart failure in patients post-myocardial infarction

Heart BMJ

1 Left ventricular ejection fraction (LVEF) is a crucial parameter in HF assessment and management, although the differences in mortality are little different between HF with LVEF≥50% or HF with preserved ejection fraction (HFpEF) in patients with post-MI compared with HF with LVEF≤40% or HF with reduced ejection fraction (HFrEF).

article thumbnail

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

DAIC

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 million adults in the U.S.

article thumbnail

Top 10: Must-reads from the Month of May

DAIC

Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10. Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial 9. Tenax Therapeutics Announces New U.S.

article thumbnail

The Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction "Twindemic” - Shared Root Causes and Treatment Targets

HeartRhythm

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We